Should cavitated bronchopulmonary cancers be considered a separate entity?

Background. This study was designed to identify any clinical, histologic, and prognostic features specific to cavitated bronchopulmonary tumors. Methods. A total of 353 patients with lung cancer were categorized in two groups on the basis of chest radiograph and computed tomographic findings: 35 patients with cavitated cancers (group I) and 318 patients with noncavitated neoplasms (group II). Cavitation was defined as the presence of air in the tumor at the time of diagnosis and before any treatment or aspiration biopsy. The two groups were compared. Results. There was no significant difference between the two groups concerning age, smoking history, or the interval to diagnosis, but diabetes (14.3% versus 5%) and fever (28.6% versus 13.5%) were significantly more frequent in group I than in group II. No statistically significant difference was observed between the two groups in tumor site or endoscopic appearance. Cavitated tumors were 1.5 times larger than the noncavitated lesions. Squamous cell carcinoma was significantly more frequent in group I than in group II (82.8% versus 61%). Survival at 1, 3, and 5 years was, respectively, 58.6%, 36.1%, and 22.2% in group I versus 48.2%, 35%, and 23.8% in group II. Conclusions. Despite several specific features, there appears to be no justification for considering cavitated neoplasms separately from other forms of lung cancer.